Moreover, high TFCP2L1 expression showed a trend towards shorter disease-specific survival times (Fig. 1B ), suggesting that high TFCP2L1 expression in HCC tissues is associated with poor prognosis in patients.
← all excerpts
TFCP2L1 drives stemness and enhances their resistance to Sorafenib treatment by modulating the NANOG/STAT3 pathway in hepatocellular carcinoma.
1
—
—